Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.
By J. Engberg, Frank Moller Aarestrup, Diane E. Taylor, P. Gerner-Smidt, I. Nachamkin. Emerging Infectious Diseases, 2001
742 citations recorded by the source corpus.
The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinolone-resistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.
Subfields: Food Science, Infectious Diseases, Small Animals
View Paper: https://www.semanticscholar.org/paper/b3b67f31c2d359f33ff6b0e6c6ea603499472acf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- P. Teixeira
- Joana G. L. Silva
- E. Ranucci
- P. Gibbs
- Mariana Fernandes
- D. Leite
- C. Mena
- P. Romagnoli
Citations in the corpus
- Campylobacter spp. as a Foodborne Pathogen: A Review (2011, background): “However, the increasing resistance to (fluoro)quinolones, tetracycline and erythromycin of C. coli and C. jejuni strains, might compromise the efficacy of this treatment (Aarestrup and Engberg, 2001; Engberg et al., 2001; Gibreel and Taylor, 2006; Alfredson and Korolik, 2007).”
- Antimicrobial resistance: A global emerging threat to public health systems (2017, background): “, 2000), timelines studies (Glynn et al., 1998; Engberg et al., 2001), microbiological studies (Shoe-”